Molecular and Cellular Studies of Human Hepatitis B Virus Variants by Ong, Hooi Tin
 xiii 
MOLECULAR AND CELLULAR STUDIES OF  
HUMAN HEPATITIS B VIRUS VARIANTS 
 
 
 
 
 
 
 
 
 
 
 
 
By 
ONG HOOI TIN 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in 
Fulfilment of the Requirements of the Degree of Doctor of Philosophy 
 
February 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
TABLE OF CONTENTS 
 
 Page 
DEDICATION ii 
ABSTRACT iii 
ABSTRAK vi 
ACKNOWLEDGEMENTS ix 
APPROVAL x 
DECLARATION xii 
LIST OF TABLES xvii 
LIST OF FIGURES xviii 
LIST OF ABBREVIATIONS xx 
  
CHAPTER  
I    INTRODUCTION 1 
  
I I   LITERATURE REVIEW 8 
2.1  Hepatitis B Infection         8 
2.2  The Virus 10 
2.3  Classification of HBV 11 
2.3.1  HBV Genotype and Clinical Outcome 12 
          2.3.2  HBV Genotype and Response to Antiviral Therapy 13 
     2.4  Viral Genome      14 
          2.4.1  HBV Core ORF 16 
          2.4.2  HBV Surface ORF 17 
          2.4.3  HBV Basal Core Promoter 18 
     2.5  HBV Pathogenesis 19 
          2.5.1  Immune-mediated Liver Injury 19 
          2.5.2  Direct Cytopathic Effect 20 
          2.5.3  Role of Viral Mutants 20 
          2.5.4  Hepatocarcinogenesis 21 
2.6  Diagnosis 21 
2.7  Treatment of Chronic Hepatitis B 23 
          2.7.1  Interferon-alpha Therapy 23 
          2.7.2  Lamivudine Therapy 24 
          2.7.3  Vaccines 25 
     2.8  HBV Mutants and Clinical Significance 27 
          2.8.1  HBV replication 27 
2.8.2  Core Promoter, Precore and Core Mutations 29 
                2.8.2.1  Basal Core Promoter (BCP) Mutations 29 
                2.8.2.2  Precore Mutations 30 
                2.8.2.3  Core Mutations 32 
2.8.2.4 BCP, Precore/Core Mutations and Interferon-α 
Responsiveness 
33 
 xv 
          2.8.3  Surface Mutations 36 
                2.8.3.1  PreS Mutations 36 
                2.8.3.2  HBsAg Mutations and Vaccine Escape         36 
                2.8.3.3  Lamivudine-selected HBsAg Protein Changes 38 
          2.8.4  Summary 39 
     2.9  Viral Control during HBV Infection 40 
          2.9.1  The Role of Cytokines in the Control of HBV Infection 41 
          2.9.2  Hepatitis B Virus-Induced Cytokine Expression 43 
          2.9.3  Cytokines in HBV Infection 44 
                2.9.3.1  Interferons 44 
                2.9.3.2  Tumour Necrosis Factor Alpha 47 
                2.9.3.4  Interleukins 48 
     2.10  HBV Infection Models 52 
  
III   MATERIALS AND METHODS 55 
     3.1  Materials 55 
          3.1.1  Serum Samples 55 
          3.1.2  DNA and RNA Extraction Reagents 55 
          3.1.3  PCR and RT-PCR Reagents 56 
          3.1.4  Gel Electrophoresis Reagents 56 
          3.1.6  Cell Line and Cell Culture Reagents 57 
          3.1.7  Equipments and Commercial Kits 57 
     3.2  Methods 58 
          3.2.1  Serum Samples 58 
          3.2.2  Extraction of HBV DNA 58 
          3.2.3  Sequence and Mutational Studies 59 
                3.2.3.1  Amplification of the HBV BCP and preC/C Genes 59 
                3.2.3.2  Amplification of the HBV preS and S Genes 59 
                3.2.3.3  Gel Purification 60 
                3.2.3.4  Sequencing and Analysis 61 
          3.2.4  HBV Genotyping 61 
                3.2.4.1  Type-Specific Primers Genotyping 61 
                3.2.4.2  Genotyping by Restriction Pattern Analysis 62 
3.2.4.3 Verification of Type-Specific Primers PCR and 
PCR-RFLP Genotype Assignments by Sequence 
Analysis 
64 
                3.2.4.4  Statistical Analysis 64 
          3.2.5  Cellular Studies of HBV Infection 65 
                3.2.5.1  Cell Culture 65 
                3.2.5.2  HBV Infection of Cell Culture 65 
                3.2.5.3  Viral DNA Extraction and Analysis 66 
                3.2.5.4  RNA Extraction 67 
                3.2.5.5  Reverse Transcription 68 
3.2.5.6 Amplification of Housekeeping Gene and Cytokine 69 
 xvi 
Genes 
3.2.5.7 Semi-quantitative Analysis of Cytokine mRNA 
Expression 
70 
  
IV   RESULTS 72 
     4.1  Sequences and Mutations 72 
          4.1.1  Basal Core Promoter and preC/C Genes 72 
          4.1.2  preS and S Genes 75 
     4.2  Subtyping 78 
     4.3  Genotyping 78 
          4.3.1  Type-Specific Primers Genotyping 78 
          4.3.2  Genotyping by PCR-RFLP Analysis 79 
          4.3.3  Verification of Genotype Assignments 82 
          4.3.4  Statistical Analysis 82 
     4.4  Cellular Studies of In-vitro HBV Infection 84 
          4.4.1  Chang Cells Culture 84 
          4.4.2  PCR Detection of HBV DNA in Infected Chang Cells 84 
          4.4.3  Cytokine Expression in In-vitro HBV infection 87 
          4.4.4  In vitro Cytokine mRNA Expression Levels 91 
                4.4.4.1  Interleukin-18 91 
                4.4.4.2  Interleukin-8 92 
                4.4.4.3  Interleukin-6 92 
                4.4.4.4  Tumour Necrosis Factor-α 92 
                4.4.4.5  Interleukin-1β 93 
                4.4.4.6  Interferon-α 93 
                4.4.4.7  Interferon-β 94 
4.4.5 Association between Cytokines Expression and HBV 
Genotypes 
94 
  
V    DISCUSSION 98 
     5.1  Clinical Data 98 
     5.2  Sequence and Mutational Studies 99 
          5.2.1  Basal Core Promoter 99 
          5.2.2  Precore Region 102 
          5.2.3  Core Region 105 
          5.2.4  PreS/S Region 108 
                5.2.4.1  Subtyping 113 
     5.3  Genotype Study 116 
          5.3.1  Genotyping Methods 116 
          5.3.2  Genotype Distribution 120 
          5.3.3  HBV Genotypes and Clinical Relevance 121 
     5.4  Cellular Studies of In Vitro HBV Infection 126 
          5.4.1  Viral DNA Detection 126 
          5.4.2  Cytokine mRNA Detection 128 
 xvii 
          5.4.3  Association of HBV Genotype and Cytokine mRNA level 133 
          5.4.4  Association of Gene Mutation and Cytokine mRNA Level 134 
  
VI   CONCLUSION AND RECOMMENDATION 137 
     6.1  Conclusion 137 
          6.1.1  Molecular Studies 137 
          6.1.2  Cellular Studeis 140 
     6.2  Recommendation for Future Work 142 
  
REFERENCES 144 
APPENDICES 182 
BIODATA OF THE AUTHOR 187 
 
 xviii 
LIST OF TABLES  
 
 
Table  Page 
2.1 HBV mutants and liver diseases 40 
   
3.1 Primer sequences used for HBV type-specific primers genotyping 62 
   
3.2 Primers used in the amplification of 18S and cytokine genes 70 
   
4.1 HBV genotype distribution in 84 HBsAg-positive samples using 
type-specific primers PCR 
78 
   
4.2 HBV genotype distribution in 50 HBsAg-positive samples using 
PCR-RFLP 
80 
   
4.3 Restriction patterns observed by action of Ava II and Dpn II on the preS 
region of HBV 
80 
   
4.4 Distribution of HBV genotypes among 84 HBsAg-positive chronic 
carriers 
82 
   
4.5 Association of HBeAg status with HBV genotypes B and C 83 
   
4.6 Risk estimate for HBV genotype C with higher HBeAg positive rate than 
HBV genotype B 
83 
   
4.7 Association of distribution of HBV genotypes with age and gender 83 
   
4.8 Semi-quantitative analysis of 18S mRNA expression in uninfected and 
infected cells 
91 
   
5.1 Amino acid substitutions located within B and T cell epitopes of HBV 
core region 
108 
   
5.2 Amino acid substitutions located within immunodominant epitopes of 
HBV preS/S region 
112 
   
5.3 The amino acid residues involved in w subdeterminants and q 
determinants recognition 
114 
   
5.4 Comparison of percent homology in nucleotide and amino acid 
sequences within the precore region (nt 1740-1838) between Bj and Ba 
isolates 
125 
 xix 
LIST OF FIGURES  
 
 
Figure  Page 
2.1 Geographical distribution of chronic hepatitis B virus infection 9 
   
2.2 Transcriptional and translational organization of the hepatitis B virus 
genome (strain ayw) 
15 
   
2.3 Organisation of the preC/C ORF and its corresponding position in 
HBV genome  
16 
   
2.4 Organisation of the preS/S ORF and its corresponding position in 
HBV genome 
18 
   
2.5 a Serological events in acute hepatitis B 22 
   
2.5 b Serological events in the progression of acute Hepatitis B infection to 
chronic carrier state 
23 
   
2.6 Essential steps involved in hepadnaviral DNA replication starting from 
a newly transcribed pgRNA template 
28 
   
2.7 Schematic representation of the stem-loop structure of the 
encapsidation signal ε in the precore region 
31 
   
2.8 Different effects of mutations in the basal core promoter and their 
function in HBeAg negative and HBeAg positive patients 
34 
   
2.9 A hypothetical two-loop structure of the ‘a’ determinant of the surface 
protein 
38 
   
4.1 PCR of BCP and preC/C genes generated a product of 898 bp 73 
   
4.2 Nucleotide substitutions found in the BCP region in asymptomatic 
patients’ serum samples 
73 
   
4.3 Amino acid sequences encoded by precore/core regions 74 
   
4.4 a PCR of preS gene showed a band of 513 bp (A), PCR of S gene 
generated a band of 778 bp (B) 
75 
   
4.5 Amino acid sequences encoded by preS gene 76 
   
 xx 
4.6 Amino acid sequences encoded by S genes 77 
   
4.7 Image of PCR product obtained from type-specific primers 
genotyping 
79 
   
4.8 Restriction patterns observed in the present study 81 
   
4.9 PCR detection of HBsAg DNA extracted from Chang cells after 20 
hours of infection and maintained in MEM, MEM-I and MEM-II for a 
further 2 days (Day 3) 
85 
   
4.10 PCR detection of HBsAg DNA extracted from Chang cells after 
infection and maintained in MEM-I at Day 1, Day 3 and Day 5 
86 
   
4.11 Gel electrophoresis of RNA extracted using Tri-Reagent 87 
   
4.12 RT-PCR detection of (a) housekeeping gene, 18S (188 bp), (b) IL-18 
(474 bp), (c) IL-8 (219 bp), (d) IL-6 (335 bp), (e) TNF-α (507 bp), (f) 
IL-1β (290 bp), (g) IFN-α (156 bp) and (h) IFN-β (178 bp) 
88-90 
   
4.13 Cytokine mRNAs expression in Chang cells infected with serum with 
HBV at Day 1, Day 3 and Day5. (a) IL-18, (b) IL-8, (c) IL-6, (d) 
TNF-α, (e) IL-1β, (f) IFN-α and (g) IFN-β 
95-96 
   
4.14 Cytokines expression profiles segregated according to HBV genotypes 
of serum used in in-vitro infection. (a) genotype C1, (b) genotype C7, 
(c) genotype C7 with basal core promoter mutations, (d) genotype B6, 
(e) genotype B1 and (f) genotype B3 
97 
   
 
 
 
 xxi 
LIST OF ABBREVIATIONS  
 
 
ε 5’ epsilon loop of HBV pregenome 
(NH4)2SO4 Ammonium sulphate 
Anti-HBc Antibody to HBcAg 
Anti-HBe Antibody to HBeAg 
anti-HBs Antibody to HBsAg 
BCP Basal core promoter 
bp Base pair 
cDNA Complementary DNA 
CHO Chineses hamster ovary 
CTL(s) Cytotoxic T lymphocyte(s) 
DCs Dendritic cells 
DEPC Diethyl pyrocarbonate 
DHBV Duck hepatitis B virus 
DMEM Dulbecco’s Minimal Essential Medium 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTPs Dideoxynucleotide triphosphates (dATP, dTTP, dCTP and dGTP) 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
Fas-L Fas ligand 
FCS Fetal calf serum 
GRP94 94-kDa glucose-regulated protein 
GSHV Ground squirrel hepatitis virus 
HBcAg Hepatitis B core antigen 
HBeAg Hepatitis B e antigen 
HBs/HBsAg Hepatitis B major surface protein/surface antigen 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
HCl  Hydrochloric acid 
HHBV Heron hepatitis B virus 
HLA Human leukocyte antigen 
HNF-1 Hepatocyte nuclear factor-1 
IFN Interferon 
IFN-α Interferon-alpha 
IFN-β Interferon-beta 
IFN-γ Interferon-gamma 
IFN-α/β Interferon-alpha or beta 
IgM Immunoglobulin M 
IKK Inhibitor of κB kinase 
IKK-α Inhibitor of κB kinase-alpha 
 xxii 
IKK-β Inhibitor of κB kinase-beta 
IL-1β Interleukin-1-beta 
IL-10 Interleukin-10 
IL-18 Interleukin-18 
IL-2 Interleukin-2 
IL-6 Interleukin-6 
IL-8 Interleukin-8 
kb Kilobase 
KCl Potassium chloride 
kDa Kilodaltons 
LHBs Hepatitis B large surface protein 
LMV Lamivudine 
MEM Minimal Essential Medium 
MgCl2 Magnesium chloride 
MHBs Hepatitis B middle surface protein 
MHC Major histocompatibility complex 
M-MLV-RT Moloney murine leukaemia virus-reverse transcriptase 
mRNA Messenger RNA 
NaCl Sodium chloride 
NF-κB Nuclear factor κB 
NK Natural killer 
nt(s) Nucleotide(s) 
ORF Open reading frame 
P/Pol HBV polymerase gene/protein 
PBMCs Peripheral blood lymphocytes 
PBS  Phosphate buffered saline 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
pgRNA Pregenomic RNA 
preC Precore 
preC/C Precore and core  
preS Hepatitis B preS genes 
preS/S preS and surface  
preS1 Hepatitis B preS1 gene 
preS2 Hepatitis B preS2 gene 
RFLP Restriction fragment length polymorphism 
RNA Ribonucleic acid 
RNase Ribonuclease 
RT Reverse transcription or reverse transcriptase 
S HBV surface region 
SDS  Sodium dodecyl sulphate 
TAE Tris acetate EDTA buffer 
Taq Thermus aquaticus thermostable DNA 
TE Tris-EDTA buffer 
 xxiii 
Th T helper  
TNF-α Tumour necrosis factor-alpha 
URR Upstream regulatory region 
UV Ultra violet 
WE William’s Medium 
WHO World health organization 
WHV  Woodchuck hepatitis virus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxiv 
CHAPTER I 
 
INTRODUCTION 
 
Despite unceasing efforts of the medical community, hepatitis B remains, besides 
hepatitis C, the most serious type of viral hepatitis and one of the major problems of 
global public health.  According to the latest World Health Organization fact sheets 
(2000), of the 2 billion people who have been infected with the hepatitis B virus (HBV), 
more than 350 million have chronic infections.  These chronically infected persons are 
at high risk of death from cirrhosis of the liver and liver cancer, diseases that kill about 1 
million persons each year (WHO, 2000).  
 
The prevalence of HBV varies tremendously in different part of the world, with a much 
higher incidence in the Eastern than in the Western Hemisphere (WHO, 2001).  High 
prevalence areas have been identified in Southeast Asia, China and Africa (reviewed by 
Lee, 1997).  About 100 million carriers, making up 75% of the world’s HBV carriers 
living in Asia, are from China (Tandon and Tandon, 1997).  In Malaysia, voluntary 
testing carried out on 17 048 healthy volunteers indicated a HBsAg seropositivity of 
5.24% (Merican et al., 2000). 
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HBV belongs to the Orthohepadnavirus genus of the Hepadnaviridae family, which is 
related to the large order of Retroid viruses (Kann and Gerlich, 1998).  Within a size of 
only about 3.2 kb, its compact, partially double-stranded DNA genome is extremely 
small, bearing four highly overlapping open reading frames (ORFs), which encode at 
least seven proteins (Kann and Gerlich, 1998; Nassal, 1999; Seeger and Mason, 2000).  
Due to the use of a viral RNA-dependent polymerase without proofreading function, 
HBV has a higher mutational rate than other DNA viruses (Blum1995; Petzold et al., 
1999).  Thus, it is generally assumed that this reverse transcription step accounts for the 
majority of point mutations and deletions or insertions that can be observed in the HBV 
genome. 
 
There are 2 major types of mutations in HBV.  Firstly, there are genotype-specific 
mutations that allow the distinction of currently eight genotypes (A-H) (Norder et al., 
1993; Stuyver et al., 2000; Arauz-Ruiz et al., 2002).  These genotypes cluster 
geographically.  Genotype A seems to represent the main European inland strain; 
genotype B and C, the Asian strain; genotype D, the Mediterranean basin strain; 
genotype E, the African strain; and genotype F, the New World strain (Norder et al., 1994; 
Magnius and Norder, 1995; Kidd Ljunggren, 1996).  Genotype G was identified in 
France and United States (Stuyver et al., 2000) and genotype H was recently encountered 
in Nicaragua, Mexico and California (Arauz-Ruiz et al., 2002).  
  
 xxvi 
The second type of HBV variability concerns mutations that emerge in an individual 
during chronic infection.  Several specific mutations of this type have been identified by 
a large number of longitudinal as well as cross-sectional studies conducted during the 
past decade (reviewed in Gunther et al., 1999).  Most of the corresponding variants 
accumulate during infection and persist as a dominant population until the late phase.  
These mutants are clinically important.  It is learned that the presence or emergence of 
specific mutations is associated with particular stages of chronic infections (Gunther et al., 
1999).    
  
In general, the enhancer II/core promoter and precore stop codon mutants appear to be 
associated with disease severity and progression (Lindh et al., 1999; Scaglioni et al., 
1997; Pult et al., 1997; Takahashi et al., 1999).  Mutations in the core antigen contribute 
strongly to immune escape at the T helper and cytotoxic T lymphocyte (CTL) level 
(Wakita et al., 1991; Chisari and Ferrari, 1995).  Recent reports also revealed that 
mutations at basal core promoter (BCP) and precore/core (preC/C) mutations may 
influence the response rate to interferon-alpha (IFN-α) therapy (Fattovich et al., 1995; 
Zhang et al., 1996; Erhardt et al., 2000).  Surface antigen mutants allow for escape from 
humoral immune responses and reduce the effectiveness of diagnostic tests and 
vaccination (Waters et al., 1992; Karthigesu et al., 1994; Carman et al., 1995,; Wallace 
and Carman, 1997; Hsu et al., 1999a).   
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HBV is a typical non-cytopathic virus that can induce tissue damage of variable severity 
by stimulating a protective immune response that can simultaneously cause damage and 
protection, by resolving intracellular virus through the destruction of virus infected cells 
(Ferrari et al., 2003).  Therefore, immune elimination of infected cells can lead to the 
termination of infection when it is efficient, or to a persistent necroinflammatory disease 
when it is not.  
 
Destruction of infected cells, however, is not the only mechanism implicated in the 
elimination of intracellular virus, as demonstrated by studies carried out in human 
hepatitis B showing the importance of cytokine-mediated, non-cytolytic mechanisms of 
antiviral protection.  The first experimental evidence in favour of such mechanisms 
derives from studies performed in the transgenic mouse model (Guidotti and Ferrari, 
2001).  These studies showed that single stranded and relaxed circular double stranded 
HBV DNA replicative intermediates can be eliminated from the cytoplasm of HBV 
transgenic hepatocytes as a result of the antiviral effect of the interferon-gamma (IFN-γ) 
and tumour necrosis factor-alpha (TNF-α) released within the transgenic liver primarily 
by infiltrating HBV-specific CD8
+
 cells (Guidotti et al., 1996; Heise et al., 1999b) but 
also CD4
+
 T cells (Franco et al., 1997).  
 
Although the existence of genotypes is known for a long period of time, only very 
recently an association of genotype and clinical outcome was proposed (Kao et al., 2000a; 
Lindh et al., 1999).  Recently, HBV genotypes have been partially clarified as 
 xxviii 
influencing the clinical manifestation of chronic liver disease in hosts.  A higher 
disease-inducing capability of genotype C than genotype B has been observed in Asia 
(Orito et al., 2001a; Kao et al., 2000a; Lindh et al., 1999).  Several studies, mostly from 
Taiwan and Japan, have shown that HBV genotype C is associated with the development 
of hepatocellular carcinoma (HCC) (Kao et al., 2000a; Ding et al., 2001; Fujie et al., 
2001) and has a lower response rate to interferon therapy as compared to genotype B 
(Kao et al., 2000b).  As for other HBV genotypes, most patients in Europe with genotype 
A have chronic hepatitis, whereas most patients with genotype D have acute hepatitis 
(Mayerat et al., 1999) and may predict the occurrence of HCC in young Indian patients 
(Thakur et al., 2002).  
 
The genotype-related differences in HBV pathogenesis have been associated with the 
HBeAg/anti-HBe status.  In the natural course of chronic HBV infection, early 
HBeAg/anti-HBe seroconversion usually associated with the cessation of virus 
replication and thus a favourable outcome (Chen, 1993).  In contrast, late seroconversion 
of HBeAg after multiple episodes of reactivation and remission may accelerate the 
progression of chronic hepatitis B and thus have a poor clinical outcome (Perillo, 2001).  
Reports have revealed that the prevalence of HBeAg is more common in HBV genotype 
C than B.  The reverse held true for the prevalence of anti-HBe, in that it is less common 
in genotype C than B (Ding et al., 2002; Chu et al., 2002; Kao et al., 2002; Orito et al., 
2001a; Kobayashi et al., 2002; Yuen et al., 2003; Akuta et al., 2003). 
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Taken together, these data from different parts of the world have lent strong support to 
possible pathogenic differences among HBV variants.  At present, those findings have 
been reported only in a few Asian countries.  Moreover, the molecular virologic 
mechanisms that contribute to these clinical differences among HBV genotypes remain to 
be explored.  The major limitation of previous studies is the lack of simple and efficient 
genotyping methods.  Genotyping of viruses by sequencing and subsequent homology 
comparison or phylogenetic tree analysis is tedious and labour intensive and, therefore, 
not practical for diagnostic purposes.  With the recent advances in molecular techniques, 
several novel genotyping methods, including polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) (Lindh et al., 1997; Mizokami et al., 1999), 
PCR with type-specific primers (Naito et al., 2001), commercial hybridization assay 
(Hou et al., 2001) and serologic genotyping assay (Usuda et al., 1999) have been 
introduced.  
  
In Malaysia, where the incidence rate of HBV was 12.19 per 100,000 population in 2001 
(Ministry of Health Malaysia, 2001), limited information on the molecular biology of the 
HBV is available.  The prevalence of HBV genotypes and the clinical relevance of HBV 
variants have not been discussed.  The studies from other areas may not apply worldwide 
because the HBV strains in various parts of the world are different, and thus the clinical 
outcome and the mechanisms responsible may be different in this country.  This 
provided a strong motivation to investigate the molecular variants of HBV in our 
population and the immune response evoked by these HBV variants. 
 xxx 
  
The objectives of this work were: 
 
1. to determine the nucleotide sequences, nucleotide variations and amino acid 
substitutions of HBV BCP, preC/C and preS/S regions in sera of asymptomatic 
chronic HBV carriers in our population; 
 
2. to investigate the prevalence of HBV genotypes using type-specific primers 
genotyping and preS amplicon restriction pattern analysis methods; 
 
3. to evaluate the genotype-related differences in respect to HBeAg status in 
chronic HBV carriers; 
 
4. to explore the genotype-related differences and BCP mutation in the expression 
of cytokines mRNA in in vitro HBV infection model.  
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CHAPTER II 
 
LITERATURE REVIEW 
 
2.1 Hepatitis B Infection 
 
The hepatitis B virus (HBV) is an aetiological agent of both acute and chronic viral 
hepatitis.  Chronic HBV infection remains a major public health problem worldwide 
with approximately 350 - 400 million chronic carriers, that is 5% of the world’s 
population (WHO, 2000).  Although clinical manifestations of the infection vary 
considerably, there is a strong correlation between chronic HBV infection and the risk of 
developing cirrhosis and hepatocellular carcinoma (HCC) (Robinson, 1994).  Of the 
chronic carriers, 25-40% will eventually die of cirrhosis with or without HCC; the death 
rate being 50% for male carriers and 15% for female carriers (Lau et al., 1997). 
 
The distribution of hepatitis B infection varies greatly throughout the world.  In African 
countries, Southeast Asia and China, the incidence is high, while in the continental 
United States and in Western Europe the incidence is relatively low (Figure 2.1).  The 
hepatitis B surface antigen (HBsAg) carrier rate varies from 0.1% to 20%.  In Northern, 
Western and Central Europe, North America and Australia, the carrier rate is relatively 
low ranging from 0.2-0.5%, while the carrier rate is intermediate ranging from 2-7% in 
Eastern Europe, the Mediterranean, Russia and the Russian Federation, Southwest Asia, 
 xxxii 
Central and South America.  In Southeast Asia, tropical Africa and parts of China, the 
carrier rates are between 8-20% of the populations (Zuckerman, 1996).   
  
In Malaysia, about 1.2-1.6% of blood donors are HBsAg positive by EIA method in 2002 
(Ministry of Health Malaysia).  Another study has shown that 5% of healthy volunteers 
are positive for HBsAg in 1997 (Merican et al., 2000). 
 
 
Figure 2.1: Geographical distribution of chronic hepatitis B virus infection (World 
Health Organization, 2001)  
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2.2 The Virus 
 
HBV was first identified in 1965 by Blumberg as a new antigen in leukaemic sera of 
native Australians and was originally referred to as the “Australia antigen” (Blumberg et 
al., 1965).  Only later was this antigen shown to be the hepatitis B virus surface antigen 
or HBsAg.  In 1970, Dane managed to isolate an infectious complete particle and 
identified it by electron microscopy (later known as Dane particle) (Dane et al., 1970).  
 
Human HBV represents the prototype of the Hepadnaviridae, a family of small DNA 
viruses that persistently infect liver cells and whose genome is the smallest known for 
mammalian viruses.  HBV shares 70% sequence homology with mammalian 
hepadnaviruses discovered in woodchucks (WHV) (Summers et al., 1978) and in various 
ground squirrel species (GSHV) (Marion et al., 1980).  Old and New World primates 
possess wild-type infection of HBV subvariants that may prove to be species specific 
(Takahashi et al., 2001).  Human HBV is, however, capable of infecting chimpanzees, 
baboons and other great apes as well as various marsupials (Seeger and Mason, 2000).  
Avian hepadnaviruses, more distantly related viruses which share a similar genome 
structure, albeit with little sequence homology to the mammalian hepadnaviruses, have 
been found in ducks (DHBV) (Mason et al., 1980), wild herons (HHBV) (Sprengel et al., 
1988) and recently in white storks (Pult et al., 2001).  Domestic geese and other hosts are 
susceptible to infection from other avian hepadnaviral species (Marion et al., 1987). 
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2.3 Classification of HBV 
 
Human hepatitis B virus can be serologically classified into four serotypes, also known as 
subtypes of HBsAg.  These were initially defined a group-specific antigenic determinant 
a which is common to all, and two pairs of mutually exclusive subtype-specific 
determinant, d/y and w/r (Le Bouvier and McCollum, 1970).  Ten subtypes, ayw1, ayw2, 
ayw3, ayw4, adw2, adw3, adw4, ayr, adrq
+
 and adrq
-
 were later identified following 
further subdivision of the w subdeterminant into w1 to w4 and the acquisition of the q 
determinant (Norder et al., 1992;1994; Arauz-Ruiz et al., 2002).  
 
  
Based on nucleotide diversity of 8% or more in the genome, HBV of various subtypes have been 
classified into 8 genotypes, designated A-H (Norder et al., 1993; Stuyver et al., 2000; Arauz-Ruiz et 
al., 2002).  The inter-relationship of subtypes to genotypes has been clarified (Orito et al., 1989).  
In general, genomes encoding adw are found in genotypes A, B, C, F and G, while the genomes 
encoding both adr and ayr occur in genotype C alongside with adw (reviewed in Kao, 2002).  HBV 
genotypes have distinct geographical distribution (Magnius and Norder, 1995; Lindh et al., 1997; 
Arauz-Ruiz et al., 1997; Stuyver et al., 2000).  Genotypes A and D are found in Africa, the 
Mediterranean area and Western Asia. Genotypes B and C prevail in Southeast Asia and the Far East, 
while genotype E circulates in Western sub-Saharan Africa (Lindh et al., 1997).  Genotype F is 
indigenous to the Ameridian populations of the New World (Telenta et al., 1997; Arauz-Ruiz et al., 
1997), and genotype G was identified in France Southeast Asia and the Far East, while 
genotype E circulates in Western sub-Saharan Africa (Lindh et al., 1997).  Genotype F 
 xxxv 
is indigenous to the Ameridian populations of the New World (Telenta et al., 1997; 
Arauz-Ruiz et al., 1997), and genotype G was identified in France and United States 
(Stuyver et al., 2000).  Genotype H was recently encountered in Nicaragua, Mexico and 
California, and was most likely split off from genotype F within the New World 
(Arauz-Ruiz et al., 2002).  
 
2.3.1 HBV Genotype and Clinical Outcome 
  
Differences in the natural history of HBV carriers and in the responses to interferon 
therapy of HBV infected patients have been described previously.  Most studies from 
East Asia, have shown that HBV genotype C is associated with more severe clinical 
outcome (Kao et al., 2000a; Fujie et al., 2001).  In Taiwan, genotype C is more prevalent 
in patients with cirrhosis compared to asymptomatic patients suggesting that the HBV 
genotype C is associated with a more severe liver disease (Kao et al., 2000a).  Ding and 
colleagues (2001) have shown that genotype C is associated with the development of 
HCC, whereas genotype B has a relatively good prognosis in China.  In Japan, the 
number of patients with liver cirrhosis or HCC increased with age in patients with 
genotype C, indicating that genotype C is also closely associated with the development of 
HCC (Orito et al., 2001a). 
 
It has been shown that although the prevalence of HBsAg among blood donors in 
Okinawa is the highest in Japan, twice as high as the average for the whole country, the 
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mortality rates for both cirrhosis and HCC in Okinawa are the lowest in Japan (Sakugawa, 
1992).  Recently, a serologic genotyping study confirmed that genotype B is the most 
prevalent HBV genotype in Okinawa (Usuda et al., 1999).  
 
As for other HBV genotypes, genotype A has been reported to be associated more 
frequently with chronic infection than genotype D in Europe (Mayerat et al., 1999).  
Recently, a prospective study was performed by Thakur and colleagues to determine the 
prevalence and clinical significance of HBV genotypes A and D in 130 histologically 
proven chronic HBV-infected Indian patients (Thakur et al., 2002).  Their results 
showed that HBV genotype D is associated with a more severe liver disease and may 
predict the occurrence of HCC in young Indian patients. 
  
2.3.2 HBV Genotype and Response to Antiviral Therapy 
 
It has been reported that HBV genotype C, compared with genotype B, is associated with 
a higher frequency of core promoter mutation and a lower response rate to IFN-α therapy 
(Kao et al., 2000b).  The data suggest that patients infected with HBV genotype B are 
predicted to have a better response to IFN-α.  A similar situation has been observed 
between HBV genotype A and D patients.  Hou and colleagues (2001) studied the 
relationship between HBV genotypes and IFN treatment response in a homogeneous 
group of 103 HBeAg positive patients with chronic hepatitis B recruited from 16  
